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Summary
To establish the contribution of germline BRCA1 and
BRCA2 mutations to familial ovarian cancer, we have
analyzed both genes in DNA samples obtained from an
affected individual in each of 112 families containing at
least two cases of epithelial ovarian cancer. Germline
mutations were found in 43% of the families; BRCA1
mutations were approximately four times more common
than BRCA2 mutations. The extent of family history of
ovarian and breast cancers was strongly predictive of
BRCA1-mutation status. Segregation analysis suggests
that a combination of chance clustering of sporadic cases
and insensitivity of mutation detection may account for
the remaining families; however, the contribution of
other genes cannot be excluded. We discuss the impli-
cations for genetic testing and clinical management of
familial ovarian cancer arising from the data presented
in these studies.
Introduction
Familial ovarian cancer occurs as part of two clinically
distinct syndromes. The most common of these syn-
dromes is ovarian cancer, which is either apparently site
specific or occurs in association with early-onset breast
cancer (Easton et al. 1993). Predisposition to ovarian
cancer also occurs as part of Lynch type II or hereditary
nonpolyposis colorectal cancer (HNPCC) syndrome
(Lynch et al. 1982). The results of genetic-linkage studies
have suggested that, in 190% of families with multiple
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cases of breast and ovarian cancer, the cancers are the
result of mutations in either the BRCA1 gene on chro-
mosome 17q12-21 or the BRCA2 gene on chromosome
13q12-13 (Narod et al. 1995; Ford et al. 1998). Linkage
data from a small series of families suggest that BRCA1
is also responsible for the majority of “site-specific ovar-
ian cancer” families with three ormore cases of epithelial
ovarian cancer (Steichen-Gersdorf et al. 1994).
Germline mutations in the BRCA1 and BRCA2 genes
have been identified in a large number of families with
multiple cases of early-onset breast and/or ovarian can-
cer (Miki et al. 1994; Shattuck-Eidens et al. 1995; Woo-
ster et al. 1995; Tavtigian et al. 1996; Gayther et al.
1997b). The mutation spectrum is similar in both genes:
most germline mutations are predicted to result in pro-
tein truncation caused by frameshift, nonsense, or splice-
site alterations, and the mutations are spread along the
length of the coding region (Breast Cancer Information
Core). A small number of founder mutations that are
common in specific populations have been described. In
particular, these include the 185delAG mutation in
BRCA1 and the 6174delT mutation in BRCA2, which
are common in Ashkenazi Jews (Struewing et al. 1995;
Neuhausen et al. 1996a, 1996b); the 5382insCmutation
in BRCA1, which is common in the eastern European
population (Gayther et al. 1997a; Ramus et al. 1997);
and the 999del5 mutation, which is common in the Ice-
landic population (Thorlacius et al. 1996). The precise
functions of the BRCA1 and BRCA2 proteins are un-
known; they have recently been shown to interact with
each other, which suggests that they may function in the
same pathway (Chen et al. 1998). Both proteins interact
in vitro with RAD51, a protein that has been implicated
in the repair of double-strand DNA breaks (Scully 1997;
Wong et al. 1997). This finding and the results of an
analysis of homozygous mutant mice suggest a possible
functional role for BRCA1 and BRCA2 in DNA repair
and genome integrity (Gayther and Ponder 1998; Zhang
et al. 1998).
An immediate consequence of the identification of the
BRCA1 and BRCA2 genes is that DNA-based predictive
testing has become possible in families when the mu-
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tation is known. Since the search for the mutation is
laborious, it is helpful to know the prevalence of BRCA1
and BRCA2 mutations in families with different cancer
histories. In this study, we set out to obtain this infor-
mation in relation to ovarian cancer. One hundred and
twelve families were ascertained to have a family history
in which at least two first- or second-degree relatives
had been given a diagnosis of epithelial ovarian cancer.
To search for disease-associated mutations, the entire
BRCA1 and BRCA2 coding sequence was analyzed in
one affected individual from each family. This enabled
us to estimate the proportion of families with ovarian
cancer that resulted from these two genes, and it also
enabled us to predict whether there are likely to be other
highly penetrant susceptibility genes that are responsible
for a proportion of cases of familial ovarian cancer.
Material and Methods
Patient Material
One hundred and three families in which at least two
first-degree relatives had epithelial ovarian cancer di-
agnosed at any age and nine families in which two cases
of epithelial ovarian cancer were diagnosed in second-
degree relatives were identified through the Familial
Ovarian Cancer Register of the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR).
To be included in the register, families must have at least
two cases of ovarian cancer confirmed by pathology re-
ports or by a death certificate. Borderline cases of ovar-
ian cancer were not included in the study. Fifty-three
families had ovarian cancer only, whereas the remaining
59 families had at least one case of breast cancer, in
addition to ovarian cancer, diagnosed in a family mem-
ber before the age of 60 years. These families included
a total of 330 cases of ovarian cancer and 133 cases of
breast cancer diagnosed before the age of 60 years. Con-
firmation of diagnosis was obtained from either pa-
thology reports or a death certificate, for a total of 281
cases of ovarian cancer and 70 cases of breast cancer.
Initial DNA analysis was performed with genomic DNA
obtained from one affected individual from each family,
and, when material was available, mutations were con-
firmed in other affected individuals from the family.
Mutation Analysis
BRCA1 and BRCA2 were both screened for germline
mutations, by use of a combination of the protein-trun-
cation test (PTT) and nonradioactive single-strand con-
formation analysis/heteroduplex analysis (SSCA/HA).
PTT was performed, as described elsewhere (Friedman
et al. 1997), for the two largest exons of BRCA2 and
for the largest exon of BRCA1. For SSCA/HA, coding
exons 2, 3, 5–10, and 12–24 of BRCA1 and coding
exons 2–9 and 12–27 of BRCA2 were amplified from
genomic DNA. The 5′ and 3′ splice boundaries of exon
11 of BRCA1 and exons 10 and 11 of BRCA2 were also
amplified from genomic DNA. Nonradioactive SSCA/
HAwas performed as described elsewhere, and gels were
visualized by silver staining (Gayther et al. 1995). Direct
sequence analysis was used to characterize the nucleotide
alteration associated with PTT and/or SSCA/HA vari-
ants, as described elsewhere (Gayther et al. 1995).
We also screened for a recently described 6-kb dupli-
cation near exon 13 of BRCA1 (Puget et al. 1999) in
families in which no BRCA1 or BRCA2 codingmutation
was identified. Duplication-specific primers (forward
primer, 5′-GATTATTTCCCCCCAGGCTA-3′; reverse
primer, 5′-AGATCATTAGCAAGGACCTGTG-3′) will
only produce a PCR-amplification product if the dupli-
cation is present in the DNA sample. Two positive ge-
nomic DNA controls for the duplication were included
in each experiment. In addition, for each sample, a sec-
ond, independent PCR reaction was simultaneously per-
formed with the use of forward primer 5′-TCACA-
ATTCCGAGACATC-3′ and reverse primer 5′-AAC-
GGCTACTGCACAGTTCT-3′. This second reaction
amplified a product with a size similar to that of the
duplication and was used to control both for the effi-
cacy of each genomic DNA sample and for PCR
amplification.
Statistical Analysis
The effects, on mutation prevalence, of the numbers
of individuals affected with breast and ovarian cancer
were assessed with the use of x2 tests for trend. To eval-
uate the evidence for existence of a third susceptibility
gene, in addition to BRCA1 and BRCA2, we performed
segregation analysis using the MENDEL program
(Lange et al. 1988). To allow for the ascertainment of
families on the basis of multiple affected individuals,
analyses were based on the conditional likelihood
Lik(M,D/D), whereM was the observed mutation status
of the index case and D was the observed disease phe-
notype in the family. BRCA1 and BRCA2 were initially
assumed to confer the age-specific risks for breast and
ovarian cancer given in previous analyses (Ford et al.
1995). Carriers of a susceptibility allele, at a hypothetical
third gene locus (OVCA) and unlinked to BRCA1 and
BRCA2, had an increased relative risk (r) of ovarian
cancer compared with noncarriers, but they had no in-
creased risk for breast cancer. Dominant, recessive, and
codominant models for OVCA were explored. The ab-
solute risks by genotype were determined by the con-
straint that the overall incidence of the disease must
agree with the incidence rates for England and Wales.
We then estimated r and the frequencies p1, p2, and p3
of the susceptibility alleles of BRCA1, BRCA2, and
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OVCA, respectively, according to maximum likelihood.
The sum was constrained to be no higher thanp  p1 2
.003, which is the combined frequency, given by the
model of Claus et al. (1991), of breast cancer–suscep-
tibility alleles and the highest plausible frequency for
BRCA1 and BRCA2 mutations combined. We also al-
lowed for a sensitivity parameter, g, which was used to
determine the probability of detecting a mutation, if one
was present (the probability was assumed to be the same
for BRCA1 and BRCA2).
We restricted consideration to those genetic models
that gave familial risks of ovarian cancer that were con-
sistent with those observed in epidemiological studies.
Stratton et al. (1998) have previously estimated that,
among first-degree relatives of patients with ovarian can-
cer, the relative risk for ovarian cancer is 2.4, with a
95% confidence interval of 1.9–3.2, on the basis of a
meta-analysis of published cohort studies. We incorpo-
rated this estimate into our analysis by adding a “pen-
alty” to the log-likelihood, to reflect deviation of risk
from 2.4: , where lo is the
2P = [log(2.4) log(l )] /2vo
predicted familial relative risk from the model andwhere
is the variance of the log (relative risk) fromv = .0177
the meta-analysis.
Results
Germline mutations, which are thought to be disease
associated, were detected in 48 (43%) of the 112 fam-
ilies. These data are listed in table 1. Twenty-nine dif-
ferent BRCA1 mutations were identified in 40 (36%) of
the 112 families. The spectrum of BRCA1 mutations in
this data set is illustrated in figure 1a. Mutations are
spread quite evenly along the length of the gene. Six
mutations were detected on more than one occasion;
these six mutations represent 43% of all BRCA1 mu-
tations identified in this study. Haplotype analysis does
not indicate a common founder mutation in the British
population (Gayther et al. 1995; Neuhausen et al.
1996b). Thirty-five (88%) of the 40 mutations are either
frameshift or nonsense mutations that would be pre-
dicted to result in premature truncation of the BRCA1
protein. Four mutations occur at the boundaries between
exons and introns and are expected to affect splicing.
The results of analysis of reverse-transcribed RNA sam-
ples obtained from two affected individuals with splice
variants (4304GrA in family OV161 and 44766TrC
in family OV003) have previously shown that these al-
terations cause aberrant splicing (Gayther et al. 1995).
There was no available RNAwith which to test the effect
of the remaining two splice-site mutations, although
both are predicted to abolish highly conserved splice-
site consensus sequences. Pro1749Arg, the putative mis-
sense mutation in family OV073, has not been described
elsewhere and was not detected in 346 normal chro-
mosomes. The functional significance of this missense
mutation has been assessed elsewhere (Chapman and
Verma 1996). The ability of the C terminus of BRCA1
to cause transcriptional activation in vitro was abolished
by a GAL4-BRCA1 fusion protein containing the
Pro1749Arg missense alteration, a finding that suggests
this change is functionally significant.
Seventy-two families without identifiable BRCA1mu-
tations were analyzed for mutations throughout the
BRCA2 coding sequence. Seven different mutations that
were considered to be pathogenic were identified in eight
(7%) of these families. The spectrum of these mutations
throughout the gene is illustrated in figure 1b. In seven
families, the mutation was a frameshift deletion, and, in
one family, it was a nonsense mutation. One mutation,
6503delTT, was detected in two different families. Two
distinct mutations seen in families OV085 and OV027
occur at nucleotide 5573, which is the beginning of a
repeat of seven adenines; this finding possibly suggests
this region is a mutation hotspot. Three putative mis-
sense mutations were also identified: A75P in exon 3
(family OV120), R2502H in exon 15 (family OV222),
and Y3098H in exon 25 (family OV045). These mu-
tations were not detected in 344, 326, and 310 normal
chromosomes, respectively. However, because these mu-
tations have an unclear disease association and because
there is no available functional assay with which to fur-
ther investigate the significance of the mutations, they
have not been included in the statistical analyses.
Subsequent to our analysis of BRCA1 and BRCA2 for
coding mutations, large genomic alterations involving
the BRCA1 gene have been reported. These alterations
would not have been detected by the PCR-based ap-
proaches to mutation screening used in our study. One
of these genomic alterations, a duplication and insertion
involving 6 kb around exon 13 of BRCA1, is predicted
to lead to protein truncation and may be of British origin
(Puget et al. 1999). A PCR-based assay has been spe-
cifically designed to detect this mutation. We were able
to screen for the exon 13 duplication in 55 families that
did not have a coding mutation in BRCA1 or BRCA2;
the mutation was not detected in any of the families
(data not shown).
Mutation Prevalence, by Family Type
Table 2 gives the proportion of families with BRCA1
and BRCA2mutations, according to the number of cases
of breast and ovarian cancer in the family. The numbers
of ovarian cancers and breast cancers in the family were
strongly predictive of BRCA1-mutation status (
2
1x =
, and , , respectively).
2
118.2 P = .0001 x = 15.29 P ! .0001
BRCA2-mutation status was significantly associated
with the number of cases of breast cancer in the family
( , ), but there was no significant asso-
2
1x = 3.80 P = .05
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Table 1
Germline Mutations in BRCA1 and BRCA2
FAMILY
NO. OF CONFIRMED
(UNCONFIRMED)
CASES OF CANCER DESCRIPTION OF MUTATION
Ovarian Breast Gene
Exon or
Intron Codon Nucleotide Alteration Type
OV010 3 (1) 1 (3) BRCA1 Exon 2 23 185 185delAG Frameshift
OV022 3 1 BRCA1 Intron 5 — 331 3312TrC Splice site
OV131 2 1 (2) BRCA1 Intron 6 — 421 421-2delA Splice site
OV047 3 (2) 2 (2) BRCA1 Exon 8 169 624TrG Gln169ter Nonsense
OV008 3 (1) 2 (2) BRCA1 Exon 11 367 1220 1220insC Frameshift
OV002 6 3 (1) BRCA1 Exon 11 392 1294 1294del40 Frameshift
OV110 2 1 BRCA1 Exon 11 392 1294 1294del40 Frameshift
OV150 4 2 BRCA1 Exon 11 392 1294 1294del40 Frameshift
OV132 3 0 (1) BRCA1 Exon 11 607 1938ArT lys607ter Nonsense
OV014 3 (3) 0 BRCA1 Exon 11 608 1942 1942del4 Frameshift
OV069 2 0 BRCA1 Exon 11 627 2000 2000del4 Frameshift
OV001 3 1 (1) BRCA1 Exon 11 652 2073 2073delA Frameshift
OV020 3 1 (1) BRCA1 Exon 11 652 2073 2073delA Frameshift
OV175 2 2 (1) BRCA1 Exon 11 655 2082 2082insG Frameshift
OV252 3 2 (2) BRCA1 Exon 11 690 2187 2190delA Frameshift
OV181 2 2 (1) BRCA1 Exon 11 871 2731 2731insT Frameshift
OV133 2 (1) 1 (1) BRCA1 Exon 11 885 2774 2774delCT Frameshift
OV171 2 0 BRCA1 Exon 11 916 2867 2867insA Frameshift
OV013 2 0 BRCA1 Exon 11 1001 3121 3121delA Frameshift
OV029 6 1 (1) BRCA1 Exon 11 1001 3121 3121delA Frameshift
OV160 2 0 BRCA1 Exon 11 1001 3121 3121delA Frameshift
OV189 3 0 BRCA1 Exon 11 1056 3286 3286delC Frameshift
OV012 7 (1) 1 BRCA1 Exon 11 1112 3452 3452del4 Frameshift
OV033 2 0 BRCA1 Exon 11 1112 3452 3452del4 Frameshift
OV007 4 (3) 0 (1) BRCA1 Exon 11 1252 3875 3875del4 Frameshift
OV206 3 (4) 0 BRCA1 Exon 11 1252 3875 3875del4 Frameshift
OV282 3 1 BRCA1 Exon 11 1252 3875 3875del4 Frameshift
OV025 3 (3) 2 BRCA1 Exon 11 1289 3986 3986delAA Frameshift
OV019 3 1 BRCA1 Exon 11 1355 4184 4184del4 Frameshift
OV042 2 (2) 1 (5) BRCA1 Exon 11 1355 4184 4184del4 Frameshift
OV044 3 (7) 0 (7) BRCA1 Exon 11 1355 4184 4184del4 Frameshift
OV245 3 0 (1) BRCA1 Exon 11 1355 4184 4184del4 Frameshift
OV161 6 1 BRCA1 Exon 12 1395 4304 4304GrA Splice site
OV226 2 (1) 0 (1) BRCA1 Exon 13 1443 4446CrT Arg1443ter Nonsense
OV003 2 (1) 2 BRCA1 Intron 13 — 4476 44766TrC Splice site
OV148 2 (1) 2 BRCA1 Exon 16 1648 5061 5061delA Frameshift
OV073 3 0 (1) BRCA1 Exon 20 1749 5365CrG Pro1749Arg Missense
OV139 2 0 (1) BRCA1 Exon 20 1755 5382 5382insC Frameshift
OV074 2 0 (1) BRCA1 Exon 24 1835 5622CrT Arg1835ter Nonsense
OV224 2 (1) 1 (7) BRCA1 Exon 24 1837 5629 5629delG Frameshift
OV092 2 (1) 2 (1) BRCA2 Exon 11 1366 4326 4326insCATC Frameshift
OV072 3 0 BRCA2 Exon 11 1491 4701 4701delGAAA Frameshift
OV140 2 1 BRCA2 Exon 11 1602 5032 5032insA Frameshift
OV027 2 1 (1) BRCA2 Exon 11 1782 5573 5573delAA Frameshift
OV085 2 0 BRCA2 Exon 11 1782 5573 5573delA Frameshift
OV254 2 (1) 0 (2) BRCA2 Exon 11 1970 6137CrA Ser1970ter Nonsense
OV016 3 4 BRCA2 Exon 11 2092 6503 6503delTT Frameshift
OV162 3 1 BRCA2 Exon 11 2092 6503 6503delTT Frameshift
ciation with the number of cases of ovarian cancer.
BRCA1 mutations were more frequent than BRCA2mu-
tations in families with large numbers of ovarian cancers;
in particular, 14 (35%) of 40 families with BRCA1 mu-
tations had four or more ovarian cancers, whereas none
of the families with BRCA2 mutations fell into this cat-
egory. However, this difference did not reach formal sta-
tistical significance ( , ).
2
1x = 2.89 P = .08
As shown in table 2, mutations were found in 66%
of families with either three or more reported cases of
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Figure 1 Location and type of germline mutations detected in (a) the BRCA1 gene and (b) the BRCA2 gene, in families containing two
or more confirmed cases of epithelial ovarian cancer.
ovarian cancer or four or more reported cases of breast
or ovarian cancer; however, they were found in only
20% of families with two cases of ovarian cancer alone.
If families are classified only on the basis of confirmed
cases, then these frequencies are altered to 71% and
22%, respectively. In the families with a BRCA1 mu-
tation, the average patient age at diagnosis of ovarian
cancer (49.9 years) was significantly lower than that in
the families without the BRCA1 mutation (53.9 years)
( ). In the families with the BRCA2 mutation,P = .003
the average age at diagnosis of ovarian cancer (55.0
years) did not differ significantly from that in either the
families with the BRCA1 mutation or the families with
no mutation.
Model Fitting
To evaluate the evidence for further ovarian can-
cer–susceptibility genes, in addition to BRCA1 and
BRCA2, we performed a segregation analysis. We tested
several models that allowed for a third gene (OVCA),
which was unlinked to BRCA1 or BRCA2 and which
had two alleles; in these models, carriers of the suscep-
tibility allele had an increased risk for ovarian cancer,
compared with noncarriers, but they had no increased
risk for breast cancer. Models were constrained for plau-
sible BRCA-gene frequencies and by the requirement
that the predicted overall incidence of breast and ovarian
cancer must agree with known incidence. The frequen-
cies of BRCA1 and BRCA2 were estimated in all models.
We did not assume any values for these parameters. The
only assumption was that their combined frequency
should not be 1.003. To assess the goodness of fit of
different genetic models to the data, we computed, for
each model, the predicted probability of observing a
BRCA1 or BRCA2 mutation in families, in different cat-
egories of family history. We then compared these pre-
dictions with what we actually observed.
Table 3summarizes the estimated parameters for some
of these models. In all but one of the models (model 4),
the relative risk conferred by the OVCA susceptibility
allele converged to 1 (i.e., there was no effect). This was
true whether OVCA was assumed to be dominant, re-
cessive, or codominant. In the case of model 4, the like-
lihood differed only slightly from that of the correspond-
ing model showing no effect of OVCA (model 4a). We
also fitted models in which the penetrance estimates for
BRCA1 and BRCA2 were reduced so that the incidence
rates for both breast and ovarian cancer were 50% of
the Breast Cancer Linkage Consortium (BCLC) esti-
mates. However, these models also converged to a rel-
ative risk of 1 for OVCA (data not shown). Models in
which the risk for breast cancer conferred by BRCA1
was given by the BCLC values (models 1 and 2) had a
poor fit, with the observed number of BRCA1 and
BRCA2 mutations being greater than the predicted num-
ber of such mutations. The models with the reduced
incidence rates, in which BRCA1 and BRCA2 were at
50% of the BCLC rates, showed a better fit than did
the models in which the actual BCLC rates were used;
however, they did not show a better fit than did the
average heterogeneity rates. Better fits were obtained in
the models in which the average of the two penetrance
estimates given by Easton et al. (1995) were assumed.
In each case, models assuming 90% sensitivity for mu-
tation detection showed better fit than did models as-
suming 64% sensitivity. Table 2 shows that, whenmodel
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Table 2
Observed and Predicted Number of Mutations, by Family Type
FAMILY HISTORY OF CANCER AND MUTATION STATUSa
NO. (%) OF FAMILIES WITH CANCER
Confirmed Casesb All Casesc
Observed Predictedd Observed Predictedd
At least two cases of ovarian cancer and at least two cases of breast cancer:
BRCA1 10 (56) 11.40 18 (56) 20.13
BRCA2 1 (5) 1.18 3 (13) 1.73
None 7 (39) 5.42 11 (31) 10.14
At least three cases of ovarian cancer and no more than one case of breast cancer:
BRCA1 17 (63) 16.37 12 (52) 11.10
BRCA2 2 (7) .68 2 (13) .90
None 8 (30) 9.75 9 (35) 11.00
Two cases of ovarian cancer and one case of breast cancer:
BRCA1 5 (29) 6.89 5 (26) 6.86
BRCA2 3 (18) .77 2 (11) .66
None 9 (53) 9.34 12 (63) 11.49
Two cases of ovarian cancer and no cases of breast cancer:
BRCA1 8 (16) 8.33 5 (13) 4.91
BRCA2 2 (4) 1.42 1 (3) .96
None 40 (80) 40.25 32 (84) 32.13
Totals:
BRCA1 40 (36) 43.00 40 (36) 43.00
BRCA2 8 (7) 4.25 8 (7) 4.25
None 64 (57) 64.76 58 (57) 64.76
a Ovarian cancer diagnosed at any age, breast cancer diagnosed at age 60 years.
b ( ) for comparison of observed and predicted numbers.2x = 4.61 P = .47
c ( ) for comparison of observed and predicted numbers.2x = 4.32 P = .50
d For the best-fitting model (model 4a) in table 3.
4a was used, the predicted mutation frequencies were
close to those observed.
Discussion
We identified germline mutations of BRCA1 or
BRCA2 in slightly less than half (43%) of 112 families
with at least two confirmed cases of epithelial ovarian
cancer in close relatives. The ratio of BRCA1 mutations
to BRCA2 mutations was 5:1. Our data confirm pre-
vious data suggesting that BRCA1 mutations are more
commonly associated with inherited susceptibility to
ovarian cancer than are BRCA2 mutations. However,
they also demonstrate that BRCA2 mutations are re-
sponsible for a significant proportion of families in
which only cases of ovarian cancer have been observed.
No BRCA1 or BRCA2 mutation was found in ∼30%
of families with an extensive family history of cancer
(families containing either three or more cases of ovarian
cancer or two or more cases of both breast and ovarian
cancer). Some mutations undoubtedly would have been
missed by the methods of mutation detection used in the
present study; PTT would have missed missense muta-
tions, and, although SSCA/HA would have been likely
to detect all small insertions and deletions, it may have
missed some single–base-pair substitutions. Becauseonly
the coding sequence of both genes was analyzed, mu-
tations occurring in the regulatory regions, which affect
transcription, would not have been detected. Evidence
of regulatory mutation was sought by looking for a re-
duction to homozygosity, in cDNA, for polymorphisms
heterozygous in genomic DNA, in the 23 families for
which RNA samples were available; however, none was
found. Because the methods used in this study were PCR
based, large genomic deletions and rearrangements in
BRCA1, similar to those that recently have been reported
elsewhere (Petrij Bosch et al. 1997; Puget et al. 1997;
Swensen et al. 1997), may have been missed. In the pre-
sent study, for those families in which no BRCA1 or
BRCA2 mutation was reported, there was insufficient
available material with which to perform Southern-blot
analysis to look for similar deletions and rearrange-
ments. However, using a mutation-specific PCR assay,
we were able to screen for a recently described dupli-
cation in BRCA1 (Puget et al. 1999); this mutation was
not detected in any of the families without BRCA1 and
BRCA2 mutations. Finally, in the majority of families,
a blood sample was available from only one affected
individual; therefore, it is possible that, in some families,
mutation analysis will have been performed on an in-
dividual who was a phenocopy.
That a substantial proportion of families had no ob-
served mutation raises the possibility that other genes
(or nongenetic familial factors) may be important de-
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Table 3
Parameters of Genetic Models Fitted to the Ovarian-Cancer Data Set
MODEL
FREQUENCY OF
RELATIVE
RISK OF OVCA
MUTATION-
DETECTION
SENSITIVITY ASSUMED RATE
PREDICTED
FAMILIAL
RISKa
LOG
LIKELIHOODBRCA1 BRCA2 OVCA
1 .0011 .0019 0 1 .64 Homogeneityb 3.15 114.1
2 .0010 .0020 0 1 .90 Homogeneityb 2.96 111.2
3 .0017 .0013 0 1 .64 Average heterogeneityc 2.00 95.4
4 .0014 .0016 .41 16,940 .90 Average heterogeneityc 2.05 93.9
4a .0014 .0016 0 1 .90 Average heterogeneityc 1.89 94.2
a Overall familial risk to first-degree relatives that is predicted by the model.
b BRCA1 rates are from the model of Easton et al. (1995), under the assumption of homogeneity; BRCA2 risks are from Ford
et al. (1998).
c BRCA1 rates are the average of incidence rates from the heterogeneity model of Easton et al. (1995); BRCA2 risks are from
Ford et al. (1998).
terminants of familial risk. In the families with either
three or more ovarian cancers or four or more early-
onset breast or ovarian cancers, those cancers are un-
likely to be caused by chance. The failure to detect mu-
tations in ∼30% of these families is, in fact, consistent
with the findings of the BCLC studies (Ford et al. 1998).
In those studies, combined linkage andmutation analysis
indicated that 195% of all families with multiple cases
of breast and ovarian cancer are accounted for by
BRCA1 and BRCA2 mutations, if a mutation-detection
sensitivity of 64% is assumed. We can therefore con-
clude, with some confidence, that, if there are additional
genes, they are of minor importance, compared with
BRCA1 and BRCA2, in families with breast and ovarian
cancer. However, because there are wide confidence lim-
its on the aforementioned estimates, the possibility of
there being one or more additional highly penetrant
genes cannot be completely excluded. To search for ev-
idence for such genes, specifically in relation to ovarian
cancer, we have so far analyzed, both by linkage and by
loss of heterozygosity at the BRCA1 and BRCA2 loci in
tumors, 11 families in which there were at least three
cases of ovarian cancer and no more than one case of
breast cancer diagnosed at age !60 years and in which
no BRCA1 or BRCA2 mutation was detected. The best
estimate based on these data (S. Ramus, unpublished
data) is that the mutation is in either BRCA1 or BRCA2
in ∼50% of such apparently mutation-negative families.
Although no single family showed strong evidence
against linkage to BRCA1 and BRCA2, it remains pos-
sible that some of the disease in these families is the
result of a mutation in other genes. One possibility
would be the mismatch-repair genes, such as MLH1 and
MSH2 (Leach et al. 1993; Papadopoulos et al. 1994).
Our preliminary results (P. Harrington, unpublished
data) indicate that the replication error–positive (RER)
phenotype expected in such cases is less frequent in tu-
mors from familial cases without mutation than it is in
sporadic ovarian cancers. This finding argues against
there being a major contribution of mutations in mis-
match-repair genes in these families with ovarian cancer,
a conclusion that must be confirmed by direct mutation
analysis of germline DNA.
A high proportion of families with only two cases of
ovarian cancer and either one or no cases of breast can-
cer had no detectable BRCA1 or BRCA2mutation. Even
if one-third of the BRCA1 and BRCA2 mutations that
were present had been missed, this would have ac-
counted for only approximately one-third of such fam-
ilies. The relative contributions of chance, nongenetic
familial factors, and genes to the remaining approxi-
mately two-thirds of families are unclear. If, for the
mother or daughter of an affected individual, the relative
risk of ovarian cancer is 2.4 (Stratton et al. 1998), then
the expected proportion of affected relative pairs caused
by chance would be 40%. However, this estimate of
relative risk encompasses all affected pairs, including
those that are part of a more extensive family history
of cases; therefore, the proportion of chance occurrences
will be higher for families with only two affected
members.
To further explore the evidence for there being other
ovarian cancer–susceptibility genes in these smaller fam-
ilies as well as in the multiple-case families, we per-
formed a segregation analysis of the entire family set.
We tested several models that allowed for the possibility
of a third ovarian cancer–specific gene in addition to
BRCA1 and BRCA2. These analyses gave no support
for the existence of a further ovarian cancer–specific
locus. We also looked for suggestions, both from the
pathology and from familial patterns of associated can-
cer, that the families without mutations might include a
distinct group. A review of the pathology has shown no
difference in the histological subtype of ovarian cancers
in familial cases with and without a BRCA1 or BRCA2
mutation, nor has it shown such a difference between
familial nonmutation cases and a consecutive hospital-
based series (Pharoah et al. 1999). The relatives in our
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39 families, in which there are only two cases of ovarian
cancer and no detectable BRCA1 or BRCA2 mutation,
do not appear to show, at sites other than the ovary and
breast, patterns of cancer that are distinct from those
seen in the families with known mutations, although the
nonuniform ascertainment and small numbers preclude
a formal comparison.
What are the implications of our data for genetic test-
ing? They indicate that testing for predisposing muta-
tions is likely to be justified in any family in which two
or more close relatives have epithelial ovarian cancer
and that testing should be directed first at the BRCA1
gene and, if this is negative, at the BRCA2 gene, possibly
starting with (but not being restricted to) the “ovarian
cancer–cluster region” (Gayther et al. 1997b). Different
germline BRCA1 and BRCA2 mutations are probably
associated with different risks for breast and ovarian
cancer (Easton 1997). We have previously reported that
mutations found in the 3′ end of the BRCA1 gene and
in a central region of the BRCA2 gene appear to be
responsible for a lower risk of ovarian cancer, relative
to the risk for breast cancer, compared with mutations
elsewhere in the gene (Gayther et al. 1995, 1997b). Both
this variation in risk and the fact that these risks may
also vary according to family history and other risk fac-
tors suggest that some caution should be used when
mutation data are used to provide precise risk estimates
for clinical management.
In families in which there are only two cases of ovarian
cancer and in which no mutation can be found, the risk
to unaffected women remains unclear. If many of these
families are, in fact, a chance association of cases, the
risks may be quite low, and measures such as prophy-
lactic oophorectomy may be inappropriate. Unlike the
familial risks of breast cancer, familial risks of ovarian
cancer do not seem to be strongly age dependent; there-
fore, the ages at which the affected individuals were di-
agnosed may not provide a reliable guide to familial risk.
Prospective data from the follow-up of unaffected
women at risk in such families will be needed to answer
this question.
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